Sign up for our daily briefing

Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on the day's biggest business stories

Subscribe to Axios Closer for insights into the day’s business news and trends and why they matter

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Stay on top of the latest market trends

Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sports news worthy of your time

Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Tech news worthy of your time

Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Get the inside stories

Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Denver news?

Get a daily digest of the most important stories affecting your hometown with Axios Denver

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Des Moines news?

Get a daily digest of the most important stories affecting your hometown with Axios Des Moines

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Twin Cities news?

Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Tampa Bay news?

Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Charlotte news?

Get a daily digest of the most important stories affecting your hometown with Axios Charlotte

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Illustration: Sarah Grillo/Axios

The Food and Drug Administration has approved a drug to treat ADHD in children for the first time in over a decade, AP reports.

Why it matters: The drug, Qelbree, is not a controlled substance or a stimulant, meaning it is harder to abuse than drugs already on the market.

What they're saying: Experts say the drug presents an opportunity for parents who want to avoid giving their child stimulants, and as a better option for kids with substance abuse problems, per AP.

  • In Supernus' late-stage study, hyperactivity and inattention symptoms in 477 children ages 6-11 were reduced by about 50% compared to the placebo group. Lethargy, headaches, and decreased appetite were common side effects.
  • Qelbree "may increase suicidal thoughts and actions in some children with ADHD, especially within the first few months of treatment or when the dose is changed," Supernus Pharmaceuticals, the manufacturer of the drug, said in a Friday press release.

Go deeper

Exclusive: Texas nonprofit got massive border contract after hiring Biden official

Migrants attempting to enter the United States from Ciudad Juarez, Mexico. Photo: David Peinado/Xinhua via Getty Images

A Texas nonprofit that recently hired a Biden transition official got a contract worth as much as $530 million to help manage the influx of migrant children at the southern border, Axios has learned.

Why it matters: The contract is by far the largest ever awarded to Family Endeavors. It's potentially worth more than 12 times the group's most recently reported annual budget — a sign of the demand the new work will place on its operations.

2 hours ago - Politics & Policy

Exclusive: $1 million ad buy defends Georgia law to business critics

Illustration: Aïda Amer/Axios

A leading conservative group is targeting the business community with a seven-figure ad buy on CNBC and local TV defending Georgia's new voting law from its corporate critics, Axios has learned.

Why it matters: By focusing on the C-suite through a network it watches, Heritage Action for America is offering a rejoinder to some companies — even Major League Baseball — after they waded so prominently into politics.